Search

Text/HTML

Remove RSS Icons CSS Edits

Google Tag Manager Code

Blog hero

Pharmacy compounding's source for clinical information, regulatory updates, and opportunities

Public Only Spacer

Banner

COMPOUND WITH CONFIDENCE: PCCA Membership, $895/month.

Live Blog Widget

Text/HTML

Blog Printing Instructions

move to publish JS changes

AdSpace For Top

Subscribe Button and Form

 

JS for ad space

The PCCA Blog

THE PCCA BLOG

rss

Stay current on PCCA news and events, market trends, and all things compounding!

BB_HRT Master Course_823x462.jpg

The numbers are in — forecasters predict 1.1 billion women worldwide will experience menopause in 2025. In the U.S., more than 1 million women reach menopause each year, and more than 75 percent of these women are employed during menopause transition years. Research conducted by the National Institute on Aging indicates menopausal hormone therapy (MHT) reduced the severity of menopause symptoms while elevating mood, sexual function, cardiovascular and brain health.

_BB_DrugWipeSampling_800w.jpg

USP 800 discusses Environmental Quality and Control (Section 6) related to environmental wipe sampling for hazardous drug (HD) surface residue. This is not a requirement in USP 800; instead, it is stated that this should be performed routinely. What does this mean for those who handle HDs and why should compounders consider performing routine HD wipe sampling?

BB_EctoSeal-Nail Fungus_800w.jpg

One of the most valuable benefits of PCCA membership is access to our knowledgeable Research & Development department and their compounding base innovations. Their creativity has led the industry and provided resources that benefit thousands of patients every day. This post focuses on a powerful base launched in 2023, EctoSeal P2G, and its application in one of the most common dermatological conditions — nail fungus (onychomycosis).

Additional Blog CSS